Intravitreal triamcinolone acetonide for idiopathic cystoid macular edema

Ingrid U. Scott, Harry W. Flynn, Philip J. Rosenfeld

Research output: Contribution to journalArticle

47 Scopus citations

Abstract

PURPOSE: To report intravitreal triamcinolone acetonide for idiopathic cystoid macular edema (ICME). DESIGN: Interventional case series. METHODS: Two patients with ICME were treated with intravitreal triamcinolone. RESULTS: In one patient, best-corrected acuity was 20/70 before treatment and 20/30 6 months posttreatment in both eyes. Foveal thickness was 606 μm before and 197 μm posttreatment in the right eye and 542 μm before and 190 μm posttreatment in the left eye. In another patient, best-corrected acuity was 20/200 before treatment and 20/50 5 months posttreatment; foveal thickness was 580 μm before and 208 μm posttreatment. Recurrence of macular edema responded to repeat intravitreal triamcinolone acetonide in both patients. CONCLUSIONS: Intravitreal triamcinolone may be associated with reduced edema and improved vision in patients with ICME; however, these changes may be transient.

Original languageEnglish (US)
Pages (from-to)737-739
Number of pages3
JournalAmerican Journal of Ophthalmology
Volume136
Issue number4
DOIs
StatePublished - Oct 1 2003

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Fingerprint Dive into the research topics of 'Intravitreal triamcinolone acetonide for idiopathic cystoid macular edema'. Together they form a unique fingerprint.

  • Cite this